| Trial ID: | L4601 |
| Source ID: | NCT01474018
|
| Associated Drug: |
Qr-Bromocriptine
|
| Title: |
QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01474018/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: QR-bromocriptine
|
| Outcome Measures: |
Primary: Change in A1c, Change from baseline HbA1c between subjects receiving QR-Bromocriptine + metformin + insulin compared to those subjects receiving metformin + insulin, Baseline - 24 weeks | Secondary: Total Daily Insulin Dose, Change in total daily insulin dose in patients treated with QR-Bromocriptine +metformin +insulin compared to metformin + insulin alone, Baseline - 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Texas Southwestern Medical Center
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-11
|
| Completion Date: |
2012-06
|
| Results First Posted: |
2019-09-16
|
| Last Update Posted: |
2019-09-16
|
| Locations: |
UT Southwestern Medical Center, Dallas, Texas, 75390, United States|UT Southwestern, Dallas, Texas, 75390, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01474018
|
